Aditxt, Inc. (ADTX) 주식 분석

회사 개요

Aditxt, Inc. (ADTX) operates as a commercial-stage biotechnology entity dedicated to discovering and developing therapeutic products within specialized domains including immune health, precision health, population health, women's health, and neurologic health. The firm has created proprietary tools such as AditxtScore, which facilitate the ability for individuals to understand, manage, and monitor their immune profiles. This company functions within the broader Healthcare sector, specifically the Biotechnology industry, a segment characterized by high research and development expenditures and significant regulatory oversight prior to product commercialization. With a market capitalization of $479,368 and annual revenue of $3,195, the firm currently employs an unspecified number of individuals, as employee count data is not publicly disclosed in available filings. The extremely low market cap figure, combined with minimal revenue generation, indicates that the company is in an early-stage development phase where capital allocation is primarily directed toward asset building rather than profit distribution or market dominance.

재무 건전성

Aditxt, Inc. reported a trailing twelve-month revenue of $3,195 alongside a net loss of $-43,101,452 and an EBITDA of $-19,301,452, revealing a substantial disconnect between top-line sales and bottom-line profitability that highlights an aggressive or inefficient cost structure typical of pre-revenue biotech firms. The company generated free cash flow of $-18,098,088, indicating that operational cash outflows significantly exceed inflows, which limits immediate financial flexibility and necessitates ongoing capital raising or existing cash reserves to fund operations. Profitability metrics show a gross margin of 8.4%, while the operating margin stands at -1098725.6% and the profit margin at 0.0%, suggesting that operating expenses are disproportionately high relative to sales or that revenue recognition methods are resulting in extreme leverage effects on the bottom line. In terms of liquidity and solvency, the company holds $3.20M in cash against $3.01M in debt, resulting in a debt-to-equity ratio of 76.04 and a current ratio of 0.31, which implies a leveraged balance sheet and potential short-term liquidity constraints given that current assets are less than half of current liabilities. Return on equity is recorded at -699.1% and return on assets at -50.3%, figures that reflect the dilution of shareholder value and the inability of management to generate returns on capital employed in the current fiscal period.

밸류에이션 평가

The valuation metrics for Aditxt, Inc. present a complex picture with a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is listed as -0.05, implying that the market currently does not anticipate positive earnings in the near future. The price-to-book ratio is reported as -0.00, which indicates that the company's market valuation is effectively zero relative to its book value, a condition often seen in speculative biotechnology stocks with significant accumulated deficits. Alternative valuation measures such as a price-to-sales ratio of 150.04 and an EV/EBITDA of 0.07 suggest that investors are pricing the company based on potential future milestones rather than current financial performance or asset backing. The stock price fluctuates within a wide 52-week range between a high of $3426.16 and a low of $0.50, meaning the current trading price sits extremely close to the absolute bottom of this historical volatility range. The beta coefficient of 1.40 indicates that the stock's price volatility is significantly higher than the broader market, exposing investors to amplified risks during periods of market turbulence.

Growth & Income

Aditxt, Inc. experienced a year-over-year revenue growth of -86.6%, while earnings growth is marked as N/A due to the absence of positive prior-year earnings, indicating that the company is currently shrinking in revenue rather than expanding its commercial footprint. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, instead retaining any minimal cash flows to attempt to fund its ongoing research and development activities. The overall growth and income profile is characterized by declining revenue, negative cash flow, and a lack of dividend income, positioning the firm as a high-risk asset that offers no current income stream to offset the risks associated with its biotechnology development pipeline.